Clene Inc. agreed to sell 1,219,513 common shares at $3.28 each, targeting approximately $4.0 million in gross proceeds. Investors should note that the planned funds are earmarked for regulatory dialogue, filings and a new drug application for CNM-Au8, as well as expanded access, potential commercialization and Manufacturing expansion.
Key Highlights
- The offering is expected to generate approximately $4.0 million in gross proceeds.
- Existing stockholders, including certain Clene directors and officers, are among the purchasers.
- Certain existing stockholders are purchasing the shares.
Clene Inc. (NASDAQ: CLNN) agreed to issue and sell 1,219,513 shares of common stock at $3.28 per share, with gross proceeds expected to reach approximately $4.0 million. The planned Capital would support regulatory dialogue and preparation of filings for lead drug candidate CNM-Au8, while also funding potential commercialization and manufacturing expansion.
$4.0M Offering Tied to CNM-Au8 Plans
The securities purchase agreement is dated September 15, 2026, and covers Clene Inc. common stock with a Par Value of $0.0001 per share. Existing stockholders, including certain directors and officers, signed as purchasers under the agreement. The closing was expected on September 17, 2026. Clene plans to combine the net proceeds with existing cash for general corporate purposes, primarily expenses connected with continued regulatory dialogue, regulatory filing preparation and a new drug application for CNM-Au8. The agreement contains customary representations, warranties, covenants, closing conditions, indemnification obligations to purchasers, other party obligations and termination provisions.
FAQs
Q: How much money will Clene Inc. raise from the stock offering?
A: Clene Inc. expects approximately $4.0 million in gross proceeds from the common stock offering. The net proceeds will be combined with existing cash.
Q: Who is purchasing Clene Inc. common stock?
A: Certain existing stockholders are purchasing the shares. The group includes certain Clene directors and officers under the securities purchase agreement.
Q: When was the Clene Inc. offering expected to close?
A: The closing was expected on September 17, 2026. The agreement covers the sale of common stock at $3.28 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.